Table 1. Patient characteristics.
| Patient no. | Age (years)/sex/symptom duration (years) | PSPRS score | FES score | Falls (per month) | DHI score | Medications |
|---|---|---|---|---|---|---|
| 1 | 76/male/4 | 30 | 20 | 2 | 40 | L-dopa |
| 2 | 79/male/5 | 19 | 19 | 0 | 10 | None |
| 3 | 75/female/4 | 38 | 61 | 8 | 58 | Amantadine, L-dopa |
| 4 | 65/male/4 | 34 | 44 | 7 | 68 | L-dopa |
| 5 | 77/female/6 | 23 | 41 | 1 | 84 | Acetyl-Dl-leucine |
| 6 | 67/female/1 | 45 | 36 | 2 | 84 | L-dopa, rotigotine |
| 7 | 64/female/2 | 30 | 41 | 7 | 52 | L-dopa |
| 8 | 65/female/2 | 10 | 24 | 2 | 48 | None |
| 9 | 74/female/4 | 28 | 53 | 4 | 68 | Donepezil |
| 10 | 75/female/5 | 43 | 46 | 2 | 76 | Rasagiline, L-dopa |
| 11 | 75/male/3 | 29 | 23 | m.d. | 46 | L-dopa |
| 12 | 72/female/2 | 13 | 33 | 0 | 36 | None |
| 13 | 78/male/2 | 43 | 40 | m.d. | 84 | None |
| 14 | 77/male/3 | m.d. | m.d. | 0 | m.d. | None |
| 15 | 78/female/6 | 43 | 44 | 1 | 68 | None |
| 16 | 67/male/4 | 34 | 24 | 6 | 38 | None |
| Mean±SD | 72.6±5.3/3.6±1.5 | 31±11 | 37±13 | 3±3 | 57±21 |
DHI: Dizziness Handicap Inventory, FES: Falls Efficacy Scale, m.d.: missing data, PSPRS: Progressive Supranuclear Palsy Rating Scale, SD: standard deviation.